The effect of PD-L1 testing on the cost-effectiveness and economic impact of immune checkpoint inhibitors for the second-line treatment of NSCLC (vol 28, pg 2256, 2017)

Journal article

Open access

Peer reviewed

P. N. Aguiar, L. A. Perry, J. Penny-Dimri, H. Babiker, H. Tadokoro, R. A. de Mello and G. L. Lopes

Annals of oncology, Vol.29(4), pp.1078-1078

2018-04-01

PMID: 29267838

Abstract

Life Sciences & Biomedicine

Oncology

Science & Technology

url

https://doi.org/10.1093/annonc/mdx478View

Published (Version of record) Open

5 Record Views

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

This output has contributed to the advancement of the following goals:

Source: InCites

Title: The effect of PD-L1 testing on the cost-effectiveness and economic impact of immune checkpoint inhibitors for the second-line treatment of NSCLC (vol 28, pg 2256, 2017)
Creators: P. N. Aguiar - Faculdade de Medicina do ABC
L. A. Perry - Monash University
J. Penny-Dimri - Monash University
H. Babiker - HonorHealth
H. Tadokoro - Universidade Federal de São Paulo
R. A. de Mello - University of Algarve
G. L. Lopes - University of Miami
Publication Details: Annals of oncology, Vol.29(4), pp.1078-1078
Publisher: Oxford Univ Press
Number of pages: 1
Academic Unit: Miller School of Medicine; UMMG Dept of Medicine - Hematology/Oncology
Language: English
Resource Type: Journal article
PMID: 29267838
Record Identifier: 991031713682502976